SEPN Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 38.02% compared to Septerna, Inc.'s net margin of 31.72%. Septerna, Inc.'s return on equity of -17.06% beat Eli Lilly & Co.'s return on equity of 106.26%.

Septerna, Inc. has a consensus price target of $29.25, signalling upside risk potential of 11.6%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,075.74 which suggests that it could grow by 6.58%. Given that Septerna, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Septerna, Inc. is more attractive than Eli Lilly & Co..

Septerna, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Septerna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Septerna, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Septerna, Inc. quarterly revenues are $21.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Septerna, Inc.'s net income of $8.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Septerna, Inc.'s price-to-earnings ratio is 66.50x while Eli Lilly & Co.'s PE ratio is 49.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Septerna, Inc. is 49.37x versus 15.49x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 38.02% compared to Septerna, Inc.'s net margin of 33.68%. Septerna, Inc.'s return on equity of -17.06% beat Merck & Co., Inc.'s return on equity of 39.63%.

Septerna, Inc. has a consensus price target of $29.25, signalling upside risk potential of 11.6%. On the other hand Merck & Co., Inc. has an analysts' consensus of $107.39 which suggests that it could grow by 8.46%. Given that Septerna, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Septerna, Inc. is more attractive than Merck & Co., Inc..

Septerna, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Septerna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.27% to investors and pays a quarterly dividend of $0.81 per share. Septerna, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Septerna, Inc. quarterly revenues are $21.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Septerna, Inc.'s net income of $8.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Septerna, Inc.'s price-to-earnings ratio is 66.50x while Merck & Co., Inc.'s PE ratio is 13.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Septerna, Inc. is 49.37x versus 3.90x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of 38.02% compared to Septerna, Inc.'s net margin of --. Septerna, Inc.'s return on equity of -17.06% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Septerna, Inc. has a consensus price target of $29.25, signalling upside risk potential of 11.6%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $53.56 which suggests that it could grow by 13.73%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Septerna, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Septerna, Inc..

Septerna, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Septerna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Septerna, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Septerna, Inc. quarterly revenues are $21.5M, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Septerna, Inc.'s net income of $8.2M is higher than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Septerna, Inc.'s price-to-earnings ratio is 66.50x while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Septerna, Inc. is 49.37x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 38.02% compared to Septerna, Inc.'s net margin of --. Septerna, Inc.'s return on equity of -17.06% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Septerna, Inc. has a consensus price target of $29.25, signalling upside risk potential of 11.6%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 150.98%. Given that Viking Therapeutics, Inc. has higher upside potential than Septerna, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Septerna, Inc..

Septerna, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Septerna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Septerna, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Septerna, Inc. quarterly revenues are $21.5M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Septerna, Inc.'s net income of $8.2M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Septerna, Inc.'s price-to-earnings ratio is 66.50x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Septerna, Inc. is 49.37x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.